Latest Listings And Ipos News

EV Resources Limited is rapidly advancing its Los Lirios Antimony Project in Mexico, unveiling extensive mineralisation and preparing for maiden drilling amid critical global supply pressures.

Vonex Limited’s shares will be suspended from ASX trading following court approval of its acquisition by Maxo Telecommunications, marking a pivotal moment for the telecom services company.

Carawine Resources Limited’s shares have been suspended from trading following a Federal Court ruling that allows QGold Pty Ltd to compulsorily acquire all remaining shares it does not own.

Nordic Resources Ltd attributes its recent share price and volume spike to a successful investor roadshow and capital raising tied to its new Finland gold projects, while confirming full ASX compliance.

Discovery Alaska Limited has detailed its exploration expenditures and strategic pivot from Alaskan projects to new US acquisitions, affirming its financial health and operational sufficiency to maintain its ASX listing.

Wellard Limited has received a final Australian Taxation Office ruling confirming its recent 15 cents-per-share return of capital is not taxable as a dividend, clarifying the tax implications for shareholders following the sale of its last revenue-generating asset.

GBM Resources has raised nearly A$40 million through a major institutional placement led by its largest shareholder, Wise Walkers Limited, to fund exploration and development in Queensland’s Drummond Basin gold projects.

Wellard Limited has formally requested to delist from the ASX following the sale of its final revenue-generating vessel, aiming to reduce costs and return excess cash to shareholders. The move awaits shareholder approval at the upcoming AGM.

Uvre Limited has gained approval for a secondary listing on the New Zealand Stock Exchange, complementing its ASX listing and enhancing access to New Zealand investors. This move aligns with its expanding gold exploration projects across New Zealand.

PYC Therapeutics has reported positive safety outcomes from its Phase 1 trial of PYC-001 for Autosomal Dominant Optic Atrophy, paving the way for a global Phase 1/2 study later this year.

EVE Health Group has raised $1.1 million to accelerate the commercial rollout of its innovative pharmaceutical products Dyspro and Libbo, signaling strong investor confidence in its growth strategy.

Austral Resources Australia Limited has extended the closing date for its $40 million placement offer to 20 October 2025, alongside an ASX suspension extension to 31 October to meet reinstatement conditions.